Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7834060 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
Mar, 2023
(a month from now) | |
US7868044 | GALDERMA LABS LP | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
Mar, 2023
(a month from now) | |
US8703820 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(a month from now) | |
US7838558 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(a month from now) | |
US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(1 year, 6 months from now) | |
US7579377 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb, 2025
(2 years from now) | |
US8709392 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep, 2026
(3 years from now) | |
US8435502 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep, 2026
(3 years from now) | |
US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(5 years from now) |
Market Authorisation Date: 19 June, 2007
Treatment: Treatment of acne; Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic